Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
BioIVT
BioIVT
Activities:
Research & Development
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Manufacturing
BioIVT acquires supplier of "human biological material" for in vitro
PrecisionMed is a leading supplier of high-quality human biological material for genetics, drug discovery, and biomarker research and in vitro diagnostics
Research & Development
BioIVT acquires Fidelis Research
The transaction increases BioIVT's network and allows it to extends to deliver fresh biospecimens and produce cell products for drug and diagnostic development
Research & Development
BioIVT acquires Cypex, a leading manufacturer of drug-metabolising enzymes
Cypex’s recombinant xenobiotic metabolising enzymes complement BioIVT’s extensive portfolio of hepatocytes and related hepatic products for drug research and development
Research & Development
BioIVT appoints Senior VP, Global Commercial Operations
Jennifer Murphy has more than 16 years’ experience in the diagnostics and life sciences industries
Research & Development
BioIVT hosting open house at London blood donor centre
The company’s Wood Lane location has expanded apheresis, whole blood, and plasma collection capabilities, as well as an on-site cell isolation laboratory
BioIVT appoints new COO
Lori Ball will move from her role as President and CEO of LAB Strategies take up the role at the provider of research models and services for drug and diagnostic development
Research & Development
Study uses fresh method to evaluate botanical-drug interactions
A whole cell model using Transporter-certified hepatocytes in sandwich culture has demonstrated that false positives might be a risk with the traditional method of analysis
Subscribe now